Safety of botulinum toxin for dysphagia in oculopharyngeal muscular dystrophy.

ABSTRACT:

Introduction

Despite multiple studies reporting marked benefit of botulinum toxin (BTX) for treatment of cricopharyngeal dysphagia, little is known about its safety for this indication. We examined the safety of cricopharyngeal BTX for dysphagia in oculopharyngeal muscular dystrophy (OPMD).

Methods

We reviewed records of patients with OPMD who received cricopharyngeal BTX.

Results

Twenty-four patients underwent 66 procedures. Overall adverse event frequency was 44%. The most common adverse events were dysphonia (24%) and worsened dysphagia (14%). Logistic regression demonstrated that dose was a significant predictor of worsened dysphagia (P = 0.036) and of the composite event of dysphonia or worsened dysphagia (P = 0.009). There was a nonsignificant trend for dose as

SUBMITTER: Youssof S 

PROVIDER: S-EPMC5215498 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature